New diabetes drug tested in kids: first results in

NCT ID NCT06362265

First seen Nov 01, 2025 · Last updated Apr 24, 2026 · Updated 22 times

Summary

This study looked at how a single dose of the experimental drug LY3209590 enters and leaves the blood in children with type 2 diabetes. Fifteen children took part, and the study lasted about 100 days. The goal was to understand the drug's processing in the body, not to treat the disease long-term.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Centricity Research Columbus Endocrinology

    Columbus, Georgia, 31904, United States

  • Children's Healthcare of Atlanta - Center for Advanced Pediatrics

    Atlanta, Georgia, 30329, United States

  • Children's Hospital Los Angeles

    Los Angeles, California, 90027, United States

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania, 19104, United States

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio, 45229-3039, United States

  • Johns Hopkins Hospital

    Baltimore, Maryland, 21287, United States

  • Joslin Diabetes Center

    Boston, Massachusetts, 02215, United States

  • Lifedoc Research - Lenox Park Drive

    Memphis, Tennessee, 38115, United States

  • NYU Langone

    New York, New York, 10016, United States

  • UBMD Pediatrics

    Buffalo, New York, 14203, United States

Conditions

Explore the condition pages connected to this study.